Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|PEPN1812||A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND #145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia||Pediatric CIRB||Available to Open|
|NRG-GY019||NRG||A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011106||Alliance||ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA8143||ECOG-ACRIN||A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1712||SWOG||A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease||Adult CIRB - Late Phase Emphasis||Available to Open|
|10184||ETCTN||Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)||Adult CIRB - Early Phase Emphasis||Available to Open|
|AALL0631||COG||A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy FLT3 Inhibition (CEP-701; Lestaurtinib; IND#76431; NSC#617807)||Pediatric CIRB||Available to Open|
|E2805||ECOG||ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|10129||ETCTN||A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|WF-97116||NCORP-Wake Forest University||A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment||Cancer Prevention and Control CIRB||Available to Open|